Delta-8 Tetrahydrocannabinol (delta-8 THC) is a psychoactive and intoxicating substance found in the Cannabis sativa plant. Delta-8 THC is different than delta-9 THC, which is illegal in Minnesota. However, delta-8 THC causes psychoactive or intoxicating effects like delta-9 THC (a "high") and has been marketed as "diet weed" or "weed light". Products containing delta-8 THC should be kept out of reach of children and pets.
Delta-8 THC products have not been evaluated or approved by the FDA for safe use and may be marketed in ways that put public health at risk. Delta-8 THC products are not approved for use in food and beverage products and these products cannot be sold in Minnesota.
The FDA and CDC have taken the initiative to provide consumers with more information about delta-8 THC due to the concerns mentioned above and an uptick in adverse event reports. Between January of 2018 and July of 2021, poison control centers nationwide have received 661 reported exposure cases, with 18% requiring hospitalization. Of the reports, 39% were pediatric patients (less than 18 years of age).
For more information, including resources for reporting adverse reactions, see the bulletin issued by the FDA and the Health Advisory issued by the CDC.
Delta-8 Tetrahydrocannabinol (delta-8 THC) is a psychoactive and intoxicating substance found in the Cannabis sativa plant. Delta-8 THC is different than delta-9 THC, which is illegal in Minnesota. However, delta-8 THC causes psychoactive or intoxicating effects like delta-9 THC (a "high") and has been marketed as "diet weed" or "weed light". Products containing delta-8 THC should be kept out of reach of children and pets.
Delta-8 THC products have not been evaluated or approved by the FDA for safe use and may be marketed in ways that put public health at risk. Delta-8 THC products are not approved for use in food and beverage products and these products cannot be sold in Minnesota.
The FDA and CDC have taken the initiative to provide consumers with more information about delta-8 THC due to the concerns mentioned above and an uptick in adverse event reports. Between January of 2018 and July of 2021, poison control centers nationwide have received 661 reported exposure cases, with 18% requiring hospitalization. Of the reports, 39% were pediatric patients (less than 18 years of age).
For more information, including resources for reporting adverse reactions, see the bulletin issued by the FDA and the Health Advisory issued by the CDC.
